

T-cell and NK-cell based immunotherapies for Lymphoid Malignancies

Milano, Starhotels Rosa Grand, September 15-16, 2023

PRELIMINARY PROGRAM

September 15, 2023

08:45 am Welcome and introduction

P. Corradini, M. Ruella, P.L. Zinzani

SESSION I – The evolving role of checkpoint inhibitors in lymphomas

Chairmen: A. Sureda, P.L. Zinzani

09:00 am Hodgkin lymphoma

A. Sureda

09:20 am Aggressive non-Hodgkin lymphoma

P.L. Zinzani

09:40 am The "chemo-sensitization" effect

P. Armand

10:00 am Novel checkpoint inhibitors

G. Collins

10:20 am Coffee break

SESSION II – Bispecific T-cell engagers in lymphoma and myeloma

Chairmen: C. Carlo-Stella, TBD

10:40 am Glofitamab

TBD

11:00 am Epcoritamab

TBD

11:20 am Mosunetuzumab

TBD

11:40 pm Odronextamab

W.S. Kim

12:00 pm IGM-2323

P. Armand

12:20 pm Teclistamab

P. Moreau

12:40 pm Talquetamab

A. Chari

01:00 pm Cevostamab

H. Einsele

01:20 pm Lunch

SESSION III – Lymphoma: Clinical updates in CAR-T therapies

Chairmen: P. Corradini, S.J. Schuster

02:20 pm	DLBCL real world data	TBD
02:40 pm	Update in DLBCL from second line (clinical trials and RWD)	M. Jain
03:00 pm	ZUMA 12 and beyond	S. Neelapu
03:20 pm	Follicular lymphoma and real world data	C.A. Jacobson
03:40 pm	Update in MCL	G. Iacoboni
04:00 pm	CAR-T in PTCL	P.M. Maciocia

SESSION IV – Innovative immunotherapy research from Italian scientists

Chairmen: A.J.M. Ferreri, M. Ladetto

04:20 pm	Roma	C. Quintarelli
04:35 pm	Monza	S. Tettamanti
05:50 pm	San Raffaele	M. Casucci
05:05 pm	Istituto Nazionale dei Tumori	C. Carniti
05:20 pm	Bologna	F. Bonifazi

05:35 pm ROUND TABLE ON SUSTAINABILITY – What about an appropriate use of commercial CAR-T

H. Einsele, M. Jain, S. Neelapu, S.J. Schuster, TBD

September 16, 2023

SESSION V – CAR-T Resistance and next-generation therapies

Chairman: M.C. Bonini, TBD

08:30 am	Mechanisms of resistance: clinical evidence	S.J. Schuster
08:50 am	Mechanisms of resistance: research	TBD
09:10 am	Gene-editing to enhance CAR-T immunotherapies	M. Ruella
09:30 am	CAR-T combinations	M. Jain
09:50 am	CAR-T in China	P. Lu

10:10 am Coffee break

SESSION VI – Novel immunotherapies for lymphoid malignancies

Chairmen: TBD, M. Ruella

10:30 am	CD30 directed CAR-T	J. Briones
10:50 am	CAR-CIK	A. Rambaldi
11:10 am	Allo CAR-T	S.S. Neelapu

11:30 am NK biAbs and NK CAR-T

K. Rezvani

11:50 am Gamma delta CAR-T19

S.S. Neelapu

SESSION VII – Hot debates in immunotherapy for lymphomas

Chairman: A. Sureda

12:10 pm Bispecific vs CAR-T

TBD vs P. Corradini

12:45 pm Is there a role for allo-SCT in lymphoma? YES vs NO

B. Glass vs S.J. Schuster

01:20 pm Lunch

SESSION VIII – T-cell immunotherapy for multiple myeloma: finally catching up!

Chairmen: M. Cavo, M.V. Mateos

02:20 pm Ide-cel

M. Cavo

02:40 pm CAR-T point of care

F. Prosper

03:00 pm Cilta-cel

TBD

03:20 pm GPRC5D CAR-T

S. Mailankody

03:40 pm Resistance

TBD

04:00 pm Next-generation approaches

M.V. Mateos

04:20 pm Conclusions and Arrivederci!